This partnership represents the first equity investment of the incubator created by HTL to accelerate the development of innovative treatments using biopolymers in therapeutic areas with unmet medical needs.
HTL will provide financial, industrial and scientific support to GelMEDIX to facilitate the development of next generation ocular and regenerative therapies based on its proprietary hydrogel platform.
This platform enables the delivery of therapeutics from small molecules to cell and gene therapies.
news from us
Articles February 10, 2024
Happy Lunar New Year 2024 !
As we step into the Year of the Dragon, we extend our warmest wishes to all our colleagues, clients, partners, and friends celebrating this joyous occasion.
Articles February 3, 2024
HTL Biotechnology at IMCAS world congress 2024
IMCAS, the world’s leading congress dedicated to dermatology, plastic surgery and aesthetics.
Articles January 17, 2024
HTL Biotechnology will be at IMCAS 2024 !
We are excited to announce that we will be participating in the IMCAS 2024 Congress !
Join us for an immersive scientific program with innovation at its core, and network with the world’s leading figures and experts in dermatology and aesthetics.
We can’t wait to see you there !